Poseida Therapeutics, Inc.’s Post

Network Medicines™ are a new class of therapeutic with the potential to transform the treatment of complex diseases that are driven by multicellular networks, such as #cancer and #fibrosis. They are designed to have both a direct effect by targeting diseased cells themselves and a network effect by reprogramming diseased cells to release therapeutic signals that coordinate other key cells in the network to restore health. Read more about Network Medicines as well as some of the other new science being pioneered by fellow #FlagshipFounded companies below. 

Today is #RNADay! #RNA is vital for transmitting genetic information, regulating genes, and enabling protein synthesis. At Elixirgen Therapeutics, we're reimagining the power of RNA by developing life-changing therapies for patients in need. Learn more: https://bit.ly/4euOyXI

Last chance to register | Expert Roundtable: Streamlining Cell and Gene Therapy Scalability With 2024 CGT approvals by the FDA anticipated to reach double figures, now more than ever it is critical to consider the end product from the earliest stages of development. We’re uniting an esteemed panel from AAVantgarde Bio, Axovia Therapeutics, Gamma Biosciences, and Nanoscope Therapeutics Inc. to uncover: - Key differences between material requirements for research vs. GMP vectors - The importance of standardizing materials and manufacturing processes - Real-world examples of how the pathway to the clinic can be streamlined Join us on May 13: https://okt.to/G1jJWb James Cody Phil Vanek Samarendra Mohanty Victor Hernandez #viralvectors #genetherapy #roundtablewebinar #humangenetherapy

Last chance to register | Expert Roundtable: Streamlining Cell and Gene Therapy Scalability With 2024 CGT approvals by the FDA anticipated to reach double figures, now more than ever it is critical to consider the end product from the earliest stages of development. We’re uniting an esteemed panel from AAVantgarde Bio, Axovia Therapeutics, Gamma Biosciences, and Nanoscope Therapeutics Inc. to uncover: - Key differences between material requirements for research vs. GMP vectors - The importance of standardizing materials and manufacturing processes - Real-world examples of how the pathway to the clinic can be streamlined Join us on May 13: https://okt.to/plBhUF James Cody Phil Vanek Samarendra Mohanty Victor Hernandez #viralvectors #genetherapy #roundtablewebinar #humangenetherapy

Epigenetic Editing Explodes on the Heels of Gene Editing Success. Coinciding with the historic approval of Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy as the first CRISPR-based therapeutic, epigenetic editing, which targets parts of the genetic code beyond the DNA itself, is having a moment. One company is already... Check out the full story 👉 https://zurl.co/ft8F (BioSpace) #biotech #genetics

Last chance to register | Expert Roundtable: Streamlining Cell and Gene Therapy Scalability With 2024 CGT approvals by the FDA anticipated to reach double figures, now more than ever it is critical to consider the end product from the earliest stages of development. We’re uniting an esteemed panel from AAVantgarde Bio, Axovia Therapeutics, Gamma Biosciences, and Nanoscope Therapeutics Inc. to uncover: - Key differences between material requirements for research vs. GMP vectors - The importance of standardizing materials and manufacturing processes - Real-world examples of how the pathway to the clinic can be streamlined Join us on May 13: https://okt.to/C19sHp James Cody Phil Vanek Samarendra Mohanty Victor Hernandez #viralvectors #genetherapy #roundtablewebinar #humangenetherapy

Do you represent a Germany or Austria based Biotechnology Company working on Market Access in Europe? Are you aware of the new EU HTA Regulation coming into force in 2025 for oncology and ATMP (cell & gene) products, and the need to submit a Joint Clinical Assessment (JCA) dossier?   If you are not yet up to speed or wondering if you are fully aware of the new requirements and how they will affect your business, please drop me a note. Our Subject Matter experts would be delighted to talk you through the implications, ensuring that you can collect and deliver appropriate evidence for a successful launch. #IQVIA #JCA #DrivingHealthcareForwardTogether #MarketAccess #WeAreIQVIA

Learn how to develop high-resolution, accurate, and robust SEC and AEX methods for nucleic acids and AAVs. Register for this on-demand webinar and explore new method parameters for designing robust and accurate separations for gene therapeutics: https://ow.ly/sUfm50TlocQ

I look forward to a productive, insightful discussion with Dr. Peter Marks

OrganoidXplore™, developed by Crown Bioscience, is a large-scale organoid panel screen, executed every three months, in which clients can include their compounds for testing on organoid viability. This assay-ready service processes up to 50 models in as little as 6 weeks ensuring your research stays ahead of the curve with rapid, data-driven decision making. It comprises a genetically characterized heterogeneous panel of tumor organoids and matching organoids derived from healthy epithelium from the same patients. Learn more in this blog post!